A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis
Open Access
- 30 December 1993
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 329 (27) , 1993-2000
- https://doi.org/10.1056/nejm199312303292704
Abstract
Dermatomyositis is a clinically distinct myopathy characterized by rash and a complement-mediated microangiopathy that results in the destruction of muscle fibers. In some patients the condition becomes resistant to therapy and causes severe physical disabilities.Keywords
This publication has 26 references indexed in Scilit:
- Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparationsThe Lancet, 1993
- Clinical, Immunopathologic, and Therapeutic Considerations of Inflammatory MyopathiesClinical Neuropharmacology, 1992
- Neutralising antibodies against C3NeF in intravenous immunoglobulinThe Lancet, 1992
- Role of Lymphocyte Adhesion Receptors in Transient Interactions and Cell LocomotionAnnual Review of Immunology, 1991
- Mitochondrial Myopathy Caused by Long-Term Zidovudine TherapyNew England Journal of Medicine, 1990
- Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.Journal of Clinical Investigation, 1989
- Intervention in autoimmune disorders: Creation of a niche for intravenous γ-globulin therapyClinical Immunology and Immunopathology, 1989
- Microvascular Deposition of Complement Membrane Attack Complex in DermatomyositisNew England Journal of Medicine, 1986
- Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositisAnnals of Neurology, 1984
- Complement activation in muscle fiber necrosis: Demonstration of the membrane attack complex of complement in necrotic fibersAnnals of Neurology, 1982